JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Harvard Bioscience Inc

Открыт

СекторЗдравоохранение

0.46 -2.13

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

0.42

Макс.

0.49

Ключевые показатели

By Trading Economics

Доход

-50M

-50M

Продажи

-2.8M

22M

Рентабельность продаж

-231.193

Сотрудники

330

EBITDA

-43M

-40M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+264.58% upside

Дивиденды

By Dow Jones

Следующий отчет о доходах

6 нояб. 2025 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

3.7M

19M

Предыдущая цена открытия

2.59

Предыдущая цена закрытия

0.46

Новостные настроения

By Acuity

37%

63%

119 / 374 Рейтинг в Healthcare

Техническая оценка

By Trading Central

Уверенность

Weak Bearish Evidence

Harvard Bioscience Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

11 авг. 2025 г., 17:49 UTC

Главные движущие силы рынка

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 авг. 2025 г., 17:18 UTC

Главные движущие силы рынка

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 авг. 2025 г., 16:25 UTC

Отчет

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 авг. 2025 г., 23:50 UTC

Обсуждения рынка

Nikkei May Rise as Yen Weakens -- Market Talk

11 авг. 2025 г., 23:42 UTC

Обсуждения рынка

Global Energy Roundup: Market Talk

11 авг. 2025 г., 23:42 UTC

Обсуждения рынка

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 авг. 2025 г., 23:36 UTC

Обсуждения рынка

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 авг. 2025 г., 23:32 UTC

Обсуждения рынка

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 авг. 2025 г., 23:02 UTC

Обсуждения рынка

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 авг. 2025 г., 20:50 UTC

Обсуждения рынка

Basic Materials Roundup: Market Talk

11 авг. 2025 г., 20:37 UTC

Отчет
Приобретения, слияния, поглощения

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 авг. 2025 г., 20:37 UTC

Отчет
Приобретения, слияния, поглощения

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 авг. 2025 г., 20:37 UTC

Отчет
Приобретения, слияния, поглощения

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 авг. 2025 г., 20:22 UTC

Отчет

Exodus Movement 2Q Rev $25.8M >EXOD

11 авг. 2025 г., 20:14 UTC

Обсуждения рынка

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 авг. 2025 г., 19:12 UTC

Обсуждения рынка

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 авг. 2025 г., 18:56 UTC

Обсуждения рынка

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 авг. 2025 г., 18:31 UTC

Обсуждения рынка

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 авг. 2025 г., 17:43 UTC

Обсуждения рынка

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 авг. 2025 г., 17:28 UTC

Обсуждения рынка

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 авг. 2025 г., 17:16 UTC

Обсуждения рынка

Commodity Longs Fall to 11-Month Low -- Market Talk

11 авг. 2025 г., 16:42 UTC

Приобретения, слияния, поглощения

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 авг. 2025 г., 16:27 UTC

Приобретения, слияния, поглощения

BBVA Says Sabadell Offer Remains in Effect

11 авг. 2025 г., 16:26 UTC

Приобретения, слияния, поглощения

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 авг. 2025 г., 16:25 UTC

Приобретения, слияния, поглощения

Banco de Sabadell Announced TSB Sale on July 1

11 авг. 2025 г., 16:25 UTC

Приобретения, слияния, поглощения

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Сравнение c конкурентами

Изменение цены

Harvard Bioscience Inc Прогноз

Целевая цена

By TipRanks

264.58% рост

Прогноз на 12 месяцев

Средняя 1.75 USD  264.58%

Максимум 3 USD

Минимум 0.5 USD

Основано на мнении 2 аналитиков Wall Street, спрогнозировавших целевые цены для Harvard Bioscience Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

2 ratings

1

Покупка

1

Удержание

0

Продажа

Техническая оценка

By Trading Central

0.3 / 0.3401Поддержка и Сопротивление

Краткосрочная

Weak Bearish Evidence

Среднесрочная

No Evidence

Долгосрочная

No Evidence

Настроения

By Acuity

119 / 374Рейтинг в Здравоохранение

Новостные настроения

Свидетельства восходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.